Current treatments

Patients’ outcome after rescue plerixafor administration for autologous stem cell mobilization: a single-center retrospective analysis. Spoerl S et al. Transfusion. 2016 Nov 18. doi: 10.1111/trf.13883. [Epub ahead of print]. Maintenance Versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma. Cornell RF et al. Biol Blood Marrow Transplant. 2016 Nov 15. pii: S1083-8791(16)30489-X. doi: 10.1016/j.bbmt.2016.11.011. [Epub ahead of print]. Absence…

Details
Journal, Library

Myeloma UK funded research identifies mechanism for genetic risk of myeloma

A study, funded by Myeloma UK, has discovered a mechanism that may explain how a genetic variant increases the risk of developing myeloma. Published in the latest issue of Nature Communications, researchers at The Institute of Cancer Research, London investigated the functional effects of the most highly associated variant they had identified from a previously conducted…

Details
News, Uncategorized

Diagnostic techniques and prognostic indicators

Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis. Oliva S et al. Oncotarget. 2016 Oct 13. doi: 10.18632/oncotarget.12641. [Epub ahead of print]. The role of 68Ga-DOTA-TATE PET/CT scanning in the evaluation of patients with multiple myeloma: preliminary results. Sonmezoglu K et al. Nucl Med Commun. 2016 Oct 21. [Epub ahead of print]. Whole body magnetic resonance imaging in…

Details
Diagnosing and Monitoring Myeloma, Journal, Library

Related conditions

Unravelling the immunopathological mechanisms of heavy chain deposition disease with implications for clinical management. Bridoux F et al. Kidney Int. 2016 Oct 20. pii: S0085-2538(16)30487-2. doi: 10.1016/j.kint.2016.09.004. [Epub ahead of print]. Polyclonal Localized Light Chain Amyloidosis-A Distinct Entity? Ravindran A et al. Clin Lymphoma Myeloma Leuk. 2016 Oct;16(10):588-592. doi: 10.1016/j.clml.2016.08.004. Prevalence, incidence and survival of smoldering multiple myeloma in the United States. Ravindran A et al. Blood Cancer…

Details
Journal, Library

Emerging treatments

Myeloma CARs are rolling into the clinical arena. Hudecek M et al. Blood. 2016 Sep 29;128(13):1667-8. doi: 10.1182/blood-2016-08-729467. Vorinostat in Combination With Lenalidomide and Dexamethasone in Lenalidomide-Refractory Multiple Myeloma. Bilotti E et al. Clin Lymphoma Myeloma Leuk. 2016 Oct;16(10):558-562. doi: 10.1016/j.clml.2016.08.001. Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib. Kumar SK et al. Blood. 2016 Oct 4. pii: blood-2016-05-717769. [Epub ahead of…

Details
Journal, Library

Biology and genetics

Cytogenetics in the management of multiple myeloma: an update by the Groupe francophone de cytogénétique hématologique (GFCH). Daudignon A et al. Ann Biol Clin (Paris). 2016 Oct 1;74(5):588-595. Hyperhaploidy is a novel high-risk cytogenetic subgroup in multiple myeloma. Sawyer JR et al. Leukemia. 2016 Oct 3. doi: 10.1038/leu.2016.253. [Epub ahead of print]. Knockdown of macrophage inhibitory cytokine-1 in RPMI-8226 human multiple myeloma cells inhibits osteoclastic…

Details
Journal, Library, Management of Myeloma

General

High-risk multiple myeloma: a multifaceted entity, multiple therapeutic challenges. Muchtar E et al. Leuk Lymphoma. 2016 Oct 13:1-14. [Epub ahead of print]. Is the revised International staging system for myeloma valid in a real world population? Walker I et al. Br J Haematol. 2016 Oct 13. doi: 10.1111/bjh.14341. [Epub ahead of print]. Progress in Myeloma – A Monoclonal Breakthrough. Rajkumar SV et al. N Engl J Med. 2016 Oct 6;375(14):1390-1392. Next-generation multiple…

Details
Journal, Library